iSonea (ASX: ISN; OTCQX: ISOAY) has appointed respected pulmonologist and venture capitalist David Dantzker to its Board.
Dantzker, a general partner at Wheatley Partners and former chairman of pulmonary disease for the American Board of Internal Medicine, has more than 10 years of medical technology portfolio management and corporate board experience.
In his current role at Wheatley Partners, Dantzker manages the medical technology portfolio of investments for the US-based $250 million venture capital fund.
Before joining Wheatley Partners, Dantzker held several executive positions, including president of North Shore-Long Island Jewish Health System, vice chairman of the Department of Internal Medicine and director of the Pulmonary and Critical Care Medicine division at the University of Texas Health Science Center.
He has also served as chairman of the American Board of Internal Medicine as well as its subspecialty board on pulmonary disease.
Dantzker's experience in both the business and clinical side of chronic respiratory disease management will be beneficial to iSonea as it moves towards the commercialisation of its asthma products.
iSonea plans to roll out a number of its asthma products over the next 24 months after entering its first formal partnership with telecommunications company Qualcomm Life for the development of a mobile asthma monitoring platform in mid-February.
The new technology will combine iSonea's proprietary Acoustic Respiratory Monitoring (ARM) ™ devices and mobile health asthma management systems with Qualcomm's 2net™ platform.
iSonea will leverage Qualcomm's 2net Hub technology, a plug-and-play connectivity gateway to the cloud-based 2net Platform data server, to collect and transmit patient health data from its asthma monitoring devices.
Importantly, the partnership will also provide iSonea with a larger scale, lower cost platform.
Last week iSonea was granted a U.S. patent covering its ultrasound-based cough detector that fits against a patient's neck and automatically detects coughs and counts coughing events.
Highlighting the strength of iSonea's product portfolio, the company now has more the 15 granted patents and numerous patent applications centred on respiratory diseases and sound analysis.